Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A novel conditioning regimen combining selinexor with melphalan  Improves Survival in Patients with multiple myeloma:a prospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLiangliang MaSYShanglun YangRLRuting Liao

Discussion

Loading...

Member takes

Overview

Prospective study shows improved efficacy and safety of the selinexor-melphalan regimen in multiple myeloma, indicating better outcomes including progression-free survival.

Key Points

  • To evaluate the safety and efficacy of a selinexor-melphalan conditioning regimen for multiple myeloma.
  • Prospective study involving 32 patients with multiple myeloma receiving selinexor and melphalan as a conditioning regimen.
  • Patients were followed for median 19 months with progression-free survival and overall survival measured.
  • Protocol adjustments were made following initial adverse events to optimize outcomes.
  • 45% of evaluable patients achieved deeper responses post-transplant with 11 patients reaching minimal residual disease-negative status.
  • Estimated 1-year progression-free survival rate was 90.9% and overall survival rate was 93.8% by Kaplan-Meier analysis.
  • No grade 4-5 hematological adverse events were observed except for initial severe vomiting in one patient.

Cite This Study

Ma et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d192https://doi.org/10.1182/blood-2025-5837
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial2025
  2. 2Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series2024 · 1 citations
  3. 3Incorporation of selinexor into conditioning regimens prior to allogeneic hematopoietic stem cell transplantation: a single-center clinical study2026
  4. 4Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study2026
  5. 5Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape2026 · 1 citations